BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1131@pharmaconomics
DTSTAMP:20260707T025829Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:LYEL Phase 3 — ronde-cel (estimated date)
DESCRIPTION:Phase 3 trial results for ronde-cel in large B-cell lymphoma (LBCL) are due ~ Dec 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/lyel-20260506x8kexx991.htm\n\nTrack it: https://pharmaconomics.com/e/1131
URL:https://pharmaconomics.com/e/1131
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:LYEL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR